Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, ...

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with drugs like Ozempic and Wegovy.

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Doctors explain why headaches are popular among Wegovy and Ozempic patients and how to treat and prevent them, including proper hydration.

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

Wegovy’s primary purpose is a weight-loss medication, while Ozempic can improve blood sugar in those living with type 2 diabetes in addition to weight loss, Megan Warnke, RDN, CDCES, tells us.

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.